Effectively targeting BRAF in melanoma: A formidable challenge

Pigment Cell and Melanoma Research

Volumn 21, Issue 4, 2008, Pages 410-411

  Fecher, Leslie A ^a   Amaravadi, Ravi ^a   Schuchter, Lynn M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; CHIR 265; MITOGEN ACTIVATED PROTEIN KINASE; PLX 4032; PLX 4720; PROPANE 1 SULFONIC ACID [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUORO PHENYL]AMIDE; RAF 265; RAF PROTEIN; SORAFENIB;

APOPTOSIS; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG TARGETING; GENE MUTATION; HUMAN; MELANOCYTE; MELANOMA; METASTASIS; MONOTHERAPY; PROTEIN FUNCTION; PROTEIN TARGETING; SHORT SURVEY; TUMOR REGRESSION;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; INDOLES; MELANOMA; POINT MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 47249142956     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2008.00485.x     Document Type: Short Survey

References (4)

1. Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949 954.
2. Sala, E., Mologni, L., Truffa, S., Gaetano, C., Bollag, G.E. Gambacorti-Passerni, C. (2008). BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells. Mol Cancer Res 6, 751 759.
3. Tsai, J., Lee, J.T., Wang, W. et al. (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041 3046.
4. Wilhelm, S.M., Carter, C., Tang, L. et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099 7109.